Journal ArticleDOI
Strategies to diversify natural products for drug discovery.
TLDR
This review provides an overview of various approaches to exploit the diversity of compounds for natural product‐based drug development, drawing upon a series of examples to illustrate each strategy.Abstract:
Natural product libraries contain specialized metabolites derived from plants, animals, and microorganisms that play a pivotal role in drug discovery due to their immense structural diversity and wide variety of biological activities. The strategies to greatly extend natural product scaffolds through available biological and chemical approaches offer unique opportunities to access a new series of natural product analogues, enabling the construction of diverse natural product-like libraries. The affordability of these structurally diverse molecules has been a crucial step in accelerating drug discovery. This review provides an overview of various approaches to exploit the diversity of compounds for natural product-based drug development, drawing upon a series of examples to illustrate each strategy.read more
Citations
More filters
Journal Article
New strategies for drug discovery: Activation of silent or weakly expressed microbial gene clusters
TL;DR: Current progress on activation of silent genes, utilization of “natural” mutant-type RNA polymerases and rare earth elements, and the applicability of ribosome engineering to myxobacteria and fungi are reviewed.
Journal ArticleDOI
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
TL;DR: A comprehensive overview of the applications of asymmetric organocatalysis in medicinal chemistry can be found in this article, with a focus on the preparation of antiviral, anticancer, neuroprotective, cardiovascular, antibacterial, and antiparasitic agents, as well as several miscellaneous bioactive agents.
Journal ArticleDOI
An overview of spirooxindole as a promising scaffold for novel drug discovery.
TL;DR: An overview of different applications and developments of spirooxindoles (including the related natural products and their derivatives) in the process of drug innovation, including such as in anticancer, antimicrobial, anti–inflammatory, analgesic, antioxidant, antimalarial, and antiviral activities is offered.
Journal ArticleDOI
Natural products for treating colorectal cancer: A mechanistic review.
TL;DR: This review generalizes the experiment-based molecular mechanisms and the regulatory networks whereby natural products exert anticancer effects on cell proliferation, metastasis, apoptosis, autophagy, and angiogenesis, and discusses the natural product-derived drugs used clinically for colorectal cancer treatment.
Microbial biotransformation as a tool for drug development based on natural products from mevalonic acid pathway: A review Production and hosting by Elsevier
Mohamed Elamir F. Hegazy,Tarik A. Mohamed,Abdelsamed I. Elshamy,Abou El-Hamd H. Mohamed,Usama A. Mahalel,Eman H. Reda,Alaa M. Shaheen,Wafaa A. Tawfik,Abdelaaty A. Shahat,Khalid A. Shams,Nahla S. Abdel Azim,F. M. Hammouda +11 more
TL;DR: Graphical abstracts as mentioned in this paper are used in this paper. But they do not specify the authorship of the abstracts, only the authors themselves, and their authorship is unknown.
References
More filters
Journal ArticleDOI
Natural Products as Sources of New Drugs from 1981 to 2014
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This contribution is a completely updated and expanded version of the four prior analogous reviews that were published in this journal in 1997, 2003, 2007, and 2012, and the time frame has been extended to cover the 34 years from January 1, 1981, to December 31, 2014, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2014 for all approved antitumor drugs worldwide.
Journal ArticleDOI
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of the three prior reviews and adds a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations.
Journal ArticleDOI
Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.
Journal ArticleDOI
Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2)
Stephen D. Bentley,Keith F. Chater,Ana Cerdeño-Tárraga,Gregory L. Challis,Gregory L. Challis,Nicholas R. Thomson,Keith D. James,David Harris,Michael A. Quail,H. M. Kieser,D. Harper,Alex Bateman,Steve D.M. Brown,Govind Chandra,Carton W. Chen,Mark O. Collins,Ann Cronin,Andrew G. Fraser,Arlette Goble,J. Hidalgo,T. Hornsby,S. Howarth,Chih-Hung Huang,Tobias Kieser,L. Larke,Lee Murphy,Karen Oliver,Susan O'Neil,Ester Rabbinowitsch,Marie-Adèle Rajandream,Kim Rutherford,Simon Rutter,Kathy Seeger,David L. Saunders,Sarah Sharp,R. Squares,S. Squares,K. Taylor,T. Warren,Andreas Wietzorrek,John Woodward,Bart Barrell,Julian Parkhill,David A. Hopwood +43 more
TL;DR: The 8,667,507 base pair linear chromosome of Streptomyces coelicolor is reported, containing the largest number of genes so far discovered in a bacterium.
Journal ArticleDOI
Target-oriented and diversity-oriented organic synthesis in drug discovery.
TL;DR: Several synthetic planning principles for diversity-oriented synthesis and their role in the drug discovery process are presented in this review.